EYEN Eyenovia Inc

Eyenovia Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 30, 2020 and Change to a Virtual Meeting Format

Eyenovia Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 30, 2020 and Change to a Virtual Meeting Format

NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it intends to convene and immediately adjourn its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) scheduled to be held on June 11, 2020 at 9:00 a.m., EDT to June 30, 2020 at 9:00 a.m., EDT, and that the adjourned meeting will be conducted exclusively in a virtual-only format by means of remote communication. Stockholders and their proxy holders will not be able to physically attend the adjourned Annual Meeting in person, however, stockholders and their proxy holders may be deemed present in person and will be able to vote and ask questions during the adjourned Annual Meeting by means of remote communication through the online platform.

The decision to adjourn the Annual Meeting and hold it in a virtual-only format was made in light of the public health and safety concerns related to the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of the Company’s stockholders, employees, and community. The means of remote communication by which stockholders and proxy holders may be deemed to be present in person and vote at the adjourned Annual Meeting will be forthcoming in a press release and also made available under the Investors – Financials – Annual Meeting Materials section of our website at after the Annual Meeting is adjourned.

About Eyenovia

Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. For more Information please visit .

Company Contact:

Eyenovia, Inc.

John Gandolfo

Chief Financial Officer

Investor Contact:

The Ruth Group

Tram Bui / Alexander Lobo

Phone: 646-536-7035/7037

/

Media Contact:

The Ruth Group

Kirsten Thomas

Phone: 508-280-6592

EN
05/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eyenovia Inc

 PRESS RELEASE

Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, Augu...

Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025 Company to host an investor conference call and webcast at 4:30 pm ET NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: HYPD), the first U.S. public company to build a strategic treasury around the HYPE token and a pioneer in integrating decentralized finance with traditional corporate treasury strategies, will host its second quarter 2025 earnings call on Wednesday, August 13, 2025, at 4:30 p.m. to review the financial and operating results. Participants should dial 1-877-407-9039 (domestic) or...

 PRESS RELEASE

Hyperion DeFi Purchases Additional $5 Million in HYPE for Kinetiq iHYP...

Hyperion DeFi Purchases Additional $5 Million in HYPE for Kinetiq iHYPE Strategy Increases total holdings to 1,535,772 HYPE Company to host investor webinar on Tuesday, July 29th at 2:00pm ET LAGUNA HILLS, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), today announced that it has acquired an additional 108,594 HYPE tokens, expanding its total holdings to 1,535,772 HYPE purchased at an average price of $36.14 per token. This latest purchase is in preparation of deploying HYPE into Kinetiq’s iHYPE (“Institutional HYPE”) po...

 PRESS RELEASE

Hyperion DeFi to Host Corporate Update Event to Discuss Strategic Evol...

Hyperion DeFi to Host Corporate Update Event to Discuss Strategic Evolution from Eyenovia and the Future of On-Chain Finance on July 29, 2025 LAGUNA HILLS, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), today announced that it will host a special corporate update event on Tuesday, July 29, 2025 at 2:00 PM ET with CIO Hyunsu Jung and CEO Michael Rowe, to discuss the Company's bold transformation from a digital ophthalmic tech company into the first publicly-listed U.S. firm focused on building a strategic treasury around HYP...

 PRESS RELEASE

Hyperion DeFi Adds $5 Million in HYPE to its Treasury Holdings

Hyperion DeFi Adds $5 Million in HYPE to its Treasury Holdings Increases total holdings to 1,427,178 HYPE LAGUNA HILLS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced that it has acquired an additional 120,726 HYPE tokens, expanding its total holdings to 1,427,178 HYPE purchased at an average price of $35.38 per token. “This latest acquisition...

 PRESS RELEASE

Eyenovia Announces Rebranding and Corporate Name Change to Hyperion De...

Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc. Name change reflects company’s leadership position with its cryptocurrency treasury reserve strategy focused on the HYPE token Company to commence trading on Nasdaq under the symbol “HYPD” effective July 3rd Also announces official launch of the Kinetiq x Hyperion validator LAGUNA HILLS, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch